A
Andrea Decensi
Researcher at University of Genoa
Publications - 92
Citations - 4483
Andrea Decensi is an academic researcher from University of Genoa. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 28, co-authored 92 publications receiving 4038 citations. Previous affiliations of Andrea Decensi include Westmead Hospital & Ente Ospedaliero Ospedali Galliera.
Papers
More filters
Journal ArticleDOI
Home Se-Cure: A Home Care Service for Cancer Patients during the COVID-19 Pandemic.
Tania Buttiron Webber,Silvia Giuliano,Carlotta Patrone,Irene Maria Briata,Maria Franconeri,Francesca Marceca,Monica Magnani,Fortuna Paciolla,Nicoletta Provinciali,Carlotta Defferrari,Matteo Clavarezza,Mauro D'Amico,Alberto Gozza,Monica Boitano,Mattia Alessio-Mazzola,Isabella Cevasco,Andrea Decensi +16 more
TL;DR: The Home Se-Cure (HSC) project as mentioned in this paper was developed to guarantee the continuity of oral, intramuscular, and subcutaneous cancer therapy during COVID-19.
Journal ArticleDOI
DNA flow cytometry as a surrogate end-point in patients with superficial bladder cancer treated with 4-HPR.
Andrea Decensi,Curotto A,Bruno S,Costantini M,Torrisi R,Beatrice Gatteschi,Cussotto M,R. Pizzorno,S. Quattrini,Repetto U +9 more
Proceedings ArticleDOI
Abstract P5-12-02: Metformin decreases Ki67 in HER2+ve ductal carcinoma in situ in a window of opportunity trial
Bernardo Bonanni,Andrea Decensi,Aliana Guerrieri-Gonzaga,Giancarlo Pruneri,Matteo Puntoni,Massimiliano Cazzaniga,Andrea Vingiani,Davide Serrano,Oreste Gentilini,Harriet Johansson,Valentina Aristarco,Matteo Lazzeroni,Clara Varicchio,Marilena Petrera,Giuseppe Viale +14 more
TL;DR: window of opportunity pre-surgical models provide insight into a drug’s preventive potential by targeting intraepithelial proliferations adjacent to invasive cancer.
Proceedings ArticleDOI
Abstract P3-13-02: Phase II randomised clinical study of first line chemotherapy plus metformin versus first line chemotherapy alone in HER2 negative, non diabetic, metastatic breast cancer patients: Final results of the MYME study
Alessandra Gennari,Oriana Nanni,Andrea Decensi,Samanta Sarti,Andrea Freschi,Alessandra Bologna,Lorenzo Gianni,Laura Amaducci,Francesco Rosetti,Filippo Giovanardi,Anna Fedeli,Massimo Ambroggi,Paolo Bruzzi,Dino Amadori +13 more
TL;DR: The addition of M to AC in MBC patients receiving first line chemotherapy did not improve PFS compared with AC alone, but M seems to have a protective effect on hematological toxicity.
Journal ArticleDOI
A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer
Carlotta Defferrari,Sara Campora,Mauro D'Amico,Arnoldo Piccardo,Ennio Biscaldi,Daniela Rosselli,Ambra Pasa,Matteo Puntoni,Alberto Gozza,Alessandra Gennari,Silvia Zanardi,Rita Lionetto,Michela Bandelloni,Andrea Decensi +13 more
TL;DR: Low-dose bevacizumab and chemotherapy was well tolerated and active in a heavily pretreated population of advanced EOC, and further studies should assess the activity of low dose bevacsuzumab in EOC.